Looking forward to presenting data at ACG2022 from our preclinical study of ADS024 highlighting its potential to improve disease activity index and reduce measures of inflammation in mice with induced colitis.
Corporate Update: Company presentation Sofinnova Partners Japan Biopharma Partnering Conference - October 19, 2022
Adiso is providing a corporate update and overview of the Adiso development programs for inflammatory disease of high unmet medical need at Sofinnova Partners Japan Biopharma Partnering Conference.
Corporate Update: Company presentation, Solebury Strategic Communications Fall Private Company Showcase - October 13, 2022
Adiso is honored to attend Solebury Strategic Communications Fall Private Company Showcase, where CEO Scott Megaffin will present our unique approach to inflammatory disease and give a progress update across our pipeline.
Corporate Update: ADS032 Poster presentation International Cytokine & Interferon Society (ICIS) - September 21, 2022
We are excited for our Head of Translational Science Ashley Mansell to present preclinical data on Adiso’s ADS032, a novel candidate blocking two types of inflammasomes NLRP1 and NLRP3 with the ability to reduce LPS-induced systemic inflammation, and silica- and IAV-mediated pulmonary disease. Click here to View the poster.
Corporate Update: ADS024 poster presentation International Congress of Parkinson’s Disease and Movement Disorders - September 17, 2022
Our Sr. Director of Research Susan Acton will be presenting data at The International Congress of Parkinson’s Disease and Movement Disorders from our preclinical study of ADS024 highlighting its potential for preventing dopamine loss and improving motor movement in Parkinson’s Disease.
Corporate Update: ADS032 poster presentation European Respiratory Society International Congress 2022 - September 2, 2022
Proudly announcing an ADS032 poster presentation at European Respiratory Society! We’ll be describing an ex-vivo study done in collaboration with The University of Edinburgh of ADS032, a dual inflammasome inhibitor with a highly differentiated anti inflammatory approach and potential use across a range of diseases.
Corporate Update: Cohorts 1 & 2 fully enrolled in our Phase 1b study - July 21, 2022
It’s with great pleasure we announce that cohorts 1 & 2 are fully enrolled in our Phase 1b study of ADS051 for the treatment of moderate to severe ulcerative colitis.
Corporate Update: Adiso at the International Narcotics Research Conference (INRC) - July 7, 2022
At the International Narcotics Research Conference (INRC) we enjoyed presenting the outstanding work of our Adiso team, a poster highlighting the impact of our SS-LBP, ADS012, on the gut-brain axis.
Corporate Update: Adiso volunteering at Food For Free - June 30, 2022
We had a blast volunteering at Food For Free. Not only was it an opportunity to help food-insecure residents in the Greater Boston Area it was also a genuinely fun team bonding experience. We packed over 360 Boxes of fresh groceries, at 25lbs each.
Corporate Update: CTO Bharat Dixit presenting at the Microbiome Movement Drug Development Summit - June 22, 2022
Our incredible CTO Bharat Dixit is presenting today on our single strain live biotherapeutic platform at the Microbiome Movement Drug Development Summit at 5pm EST.
Corporate Update: Adiso presents at the BIO International Convention - June 9, 2022
We’ll be attending this year’s BIO International Convention! On June 13 at 1:15 p.m. PDT, we will be giving a company presentation on our innovative pipeline of small molecules and single strain live biotherapeutic products to treat inflammatory diseases.
Corporate Update: ADS024 manuscript published in Scientific Reports - June 6, 2022